A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 214
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : tPSA
Long Form : total prostate-specific antigen
No. Year Title Co-occurring Abbreviation
2023 A Novel Nomogram Combined the Aggregate Index of Systemic Inflammation and PIRADS Score to Predict the Risk of Clinically Significant Prostate Cancer. AISI, AUC, csPCa, DCA, PI-RADS, PV, ROC
2023 Amide Proton Transfer-weighted MRI combined with serum prostate-specific antigen levels for differentiating malignant prostate lesions from benign prostate lesions: a retrospective cohort study. APT, AUC, AUC, DCE, DWI, fPSA, MRI, PSA, PSAD, ROC, T2WI
2023 Clinical analysis of transurethral holmium laser enucleation in the treatment of benign prostatic hyperplasia with prostatic inflammation: A prospective research study. BMI, BPH, BPH group, fPSA, HoLEP, IPSS, PI, PV, PVR, QoL
2023 Robot-assisted radical resection in prostate cancer comparative assessment with conventional laparoscopic prostatectomy: a retrospective comparative cohort study with single-center experience. BMI, DVRS, LS
2022 Association between total prostate-specific antigen (tPSA), free/tPSA, and prostate cancer mortality. ---
2022 Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. ctDNA, HRR, mCRPC, PALB2
2022 Exploration of the Value of Combined UA, IL-6, and fPSA/tPSA in the Diagnosis of Prostate Cancer. fPSA, IL-6, PCa, ROC, UA
2022 FruHis significantly increases the anti-benign prostatic hyperplasia effect of lycopene: A double-blinded randomized controlled clinical trial. BMI, BPH, fPSA, IGF-1, WC
2022 Incidence and associated factors for incidental prostate cancer among patients who underwent surgery for benign prostatic hyperplasia: first report from Somalia. IPC, ISUP, OP, TURP
10  2022 Potential factors of cytokeratin fragment 21-1 and cancer embryonic antigen for mediastinal lymph node metastasis in lung cancer. AFP, ALP, CEA, Hb, NSE, ROC
11  2022 Predictive value of PSA density in the diagnosis of prostate cancer in lebanese men. PSAD
12  2022 Prevalence of skeletal-related events in hormone-naive prostate cancer in a low resource setting. CI, GS, LUTS, OR, SREs
13  2022 Prostate cancer characteristics: A descriptive analysis of clinical features at presentation in the last decade in a black African community. GS
14  2022 Radiomic Machine Learning and External Validation Based on 3.0 T mpMRI for Prediction of Intraductal Carcinoma of Prostate With Different Proportion. ADC, DCE, DWI, GS, IDC-P, mpMRI, PAC, PCa, ROC-AUC
15  2022 Retrospective analysis of risk factors for bone metastasis in newly diagnosed prostate cancer patients. ALP, ESR, fPSA, PCa
16  2022 Risk factors of bone metastasis in patients with newly diagnosed prostate cancer. ALP, BMT, BMT, ECT, None-BMT, PCa, PCBM, PSAD
17  2022 Survival Analysis and a Novel Nomogram Model for Progression-Free Survival in Patients with Prostate Cancer. ALP, PCa, PFS
18  2022 The Indicative Value of Serum Tumor Markers for Metastasis and Stage of Non-Small Cell Lung Cancer. AUC, CA199, CEA, NSCLC, NSE, ProGRP, SCC-Ag
19  2022 Total Prostate Specific Antigen in Prostate Cancer Screening in Hyperglycemic Individuals. FBG
20  2022 Ultrasound-based radiomics score for pre-biopsy prediction of prostate cancer to reduce unnecessary biopsies. AUC, CI, LASSO, PBs, PCa, TRUS, US
21  2022 [Microfocal prostate cancer: a clinicopathological analysis of 206 cases]. EPE, fPSA
22  2021 A Large Number of Fresh Samples and a Wide Range of Total Prostate-Specific Antigen (tPSA) Concentrations Is Important to Detect Differences in PSA Methods. ---
23  2021 Based on biomedical index data: Risk prediction model for prostate cancer. APOE, OR, ROC, TG
24  2021 Cardiac, Hepatic and Renal Dysfunction and IL-18 Polymorphism in Breast, Colorectal, and Prostate Cancer Patients. ALP, ARMS, AST, CA15-3, CA19-9, CEA, CK-MB, CRC, hs-cTnT, IL, MI, OR, PCa
25  2021 Effect of Combining Traditional Chinese Medicine with Hormonal Therapy on Quality of Life and Tumor Markers of Prostate Cancer Patients. FACT-P, fPSA, TCM
26  2021 Efficacy and Prognostic Factors of Androgen Deprivation Therapy Combined with Radiation Therapy for Prostate Cancer. ADT, mPFS, OS, VEGF
27  2021 Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET/CT: a real-world study. AUC, BPD, csPCa, DRE, GS, mpMRI, NPV, PCa, PET/CT, PPV, ROC
28  2021 Retrospective observation of the efficacy and safety of prostatic artery embolization combined with transurethral resection of the prostate and simple transurethral resection of the prostate in the treatment of large (> 100mL) benign prostatic hyperplasia. BL, BPH, fPSA, IPSS, OT, PAE, PBFT, PCRT, PV, PVR, QoL, SEL, TURP
29  2021 The influence of age on prostate cancer screening index. AUC, AVR, fPSA, PCa, PSAD, ROC
30  2020 Added Value of Biparametric MRI and TRUS-Guided Systematic Biopsies to Clinical Parameters in Predicting Adverse Pathology in Prostate Cancer. AUC, bpMRI, CTZV, DCAs, EPE, PCa, SVI, TRUS
31  2020 Analysis of Prostate-Specific Antigen-Related Indexes, Neutrophil-to-Lymphocyte Ratio in Patients with Concurrent Benign Prostatic Hyperplasia and Histologic Prostatitis. BPH, fPSA, NLR, tPSAD
32  2020 Assessment of Serum Tumor Markers for Predicting Ocular Metastasis in Lung Adenocarcinoma: A Retrospective Study. AFP, CEA, OM
33  2020 Biomarkers That Differentiate Benign Prostatic Hyperplasia from Prostate Cancer: A Literature Review. BPH
34  2020 Can continuous positive airway pressure improve lower urinary tract symptoms and erectile dysfunction in male patients with severe obstructive sleep apnea syndrome? CPAP, IPSS, OSAS
35  2020 Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia. AUC, BPH, miRNAs, PCa, ROC
36  2020 Clinical value of prostate-specific antigen combined with tumor abnormal protein (TAP) in the diagnosis of prostate puncture. fPSA, TAP
37  2020 Correlation between prostate-specific antigen and four renal function-associated parameters in different ethnicities in southwest China. ---
38  2020 DNA Nanofirecrackers Assembled through Hybridization Chain Reaction for Ultrasensitive SERS Immunoassay of Prostate Specific Antigen. AA, AAP, C-HCR, SA-ALP, SERS
39  2020 Highly Selective Optical Sensor Eu (TTA)3 Phen Embedded in Poly Methylmethacrylate for Assessment of Total Prostate Specific Antigen Tumor Marker in Male Serum Suffering Prostate Diseases. FRET, PMMA, SEM, XRD
40  2020 Ocular Metastasis in Elderly Lung Cancer Patients: Potential Risk Factors of CA-125, CA-153 and TPSA. NOM, NSE, OM, ROC
41  2020 Prostate volume does not provide additional predictive value to prostate health index for prostate cancer or clinically significant prostate cancer: results from a multicenter study in China. AUC, fPSA, PCa, PHI, PHID, PV
42  2020 Risk Factors for Pathologically Confirmed Lymph Nodes Metastasis in Patients With Clinical T2N0M0 Stage Prostate Cancer. GGG, IDC-P, PCa, PI-RADSv2
43  2020 Serum total prostate-specific antigen (tPSA): correlation with diagnosis and grading of prostate cancer in core needle biopsy. PSA
44  2020 The Combination of CA125 and NSE Is Useful for Predicting Liver Metastasis of Lung Cancer. CA125, CA153, CA199, CEA, CYFRA21-1, NSE
45  2020 The importance of PSA-Density in active surveillance for prostate cancer. AS, PCa, PSAD
46  2020 [Clinical value of serum isoform [-2] proprostate-specific antigen and its derivatives in predicting aggressive prostate cancer]. AUC, fPSA, PCa, PHI, ROC
47  2020 [Relationship of prostate volume and inflammatory cell infiltration with the positive rate of prostate biopsy]. BMI, ICI, PSAD
48  2020 [Single-center study of the abnormal concentration of bone imaging agent and prostate cancer bone metastasis prediction model]. F/T, PCa, ROC, ROI
49  2019 Comparing clinical parameters of abnormal and normal fasting blood glucose in benign prostatic hyperplasia patients. BPH, FBG, HR-T2DM, IFG, IPSS, PV
50  2019 Diagnostic performance of 68Ga-PSMA PET/CT in the detection of prostate cancer prior to initial biopsy: comparison with cancer-predicting nomograms. NPV, PCa, PPV, ROC
51  2019 Establishing a prediction model for prostate cancer bone metastasis. ALP, bGS, BM, fPSA, PCa
52  2019 Family history is significantly associated with prostate cancer and its early onset in Chinese population. BRCA, FH, PCa, RR
53  2019 Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen-age volume. mpMRI, PCa, PI-RADSv2, PSA-AV, PSAD
54  2019 p2PSA for predicting biochemical recurrence of prostate cancer earlier than total prostate-specific antigen after radical prostatectomy: an observational prospective cohort study. RALP, RP
55  2019 Prostate health index is useful for prostate cancer detecting in Chinese people. AUC, fPSA, PCa, PHI
56  2019 Specific Biomarkers of Prostate Cancer-Associated Ischemic Stroke: A Case-Control Study. AUC, CaIS, NLR, PCa, ROC
57  2019 Transperineal intraprostatic injection of botulinum neurotoxin A vs transurethral resection of prostate for management of lower urinary tract symptoms secondary to benign prostate hyperplasia: A prospective randomised study. BoNT-A, BPH, IPSS, LUTS, PV, PVR, TURP
58  2018 Application of Six Sigma for evaluating the analytical quality of tumor marker assays. AFP, CA125, CA153, CA199, CEA, TEa
59  2018 Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study. p2PSA, PCa, PHI
60  2018 Diagnostic value of total prostate specifc antigen (TPSA) in women with breast cancer in the molecular subtyping era. CA 15.3, CEA
61  2018 Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies. BPH, PCa, PEDF, VEGF
62  2018 Performance of the 4Kscore Test in Plasma and Serum and Stability of the Component Analytes in Clinical Samples. FDA, fPSA, hK2, iPSA
63  2018 Selected landscape phage probe as selective recognition interface for sensitive total prostate-specific antigen immunosensor. DPV, ELISA
64  2018 Sensitivity Enhancement of Forster Resonance Energy Transfer Immunoassays by Multiple Antibody Conjugation on Quantum Dots. Ab, FRET, QDs
65  2018 Using the prostate imaging reporting and data system version 2 (PI-RIDS v2) to detect prostate cancer can prevent unnecessary biopsies and invasive treatment. csPCa, PCa, PI-RADSv2, PI-RIDS v2, PSAD
66  2018 [Transurethral resection of prostate treatment for recurrence of a multilocular prostatic cystadenoma: a case report]. fPSA, IPSS, MPC, QoL, TURP
67  2017 Comparison of the clinical parameters of benign prostate hyperplasia in diabetic and non diabetic patients. BMI, BPH, IPSS
68  2017 Does Preoperative Use of Dutasteride Decrease Bleeding During Open Prostatectomy? Hct, Hgb, OP
69  2017 Does the Prostate Health Index Depend on Tumor Volume?-A Study on 196 Patients after Radical Prostatectomy. AUC, fPSA, PCa, PHI, pT stage
70  2017 Dual-labeled chemiluminescence enzyme immunoassay for simultaneous measurement of total prostate specific antigen (TPSA) and free prostate specific antigen (FPSA). ALP, AMPPD, CLEIA, fPSA, fPSA, HRP, PSA
71  2017 Pediatric reference intervals for 29 Ortho VITROS 5600 immunoassays using the CALIPER cohort of healthy children and adolescents. beta-hCG, CA125, CA15-3, CK-MB, fPSA, FSH, iPTH, LH, RIs, rubella IgG
72  2017 The establishment and evaluation of a new model for the prediction of prostate cancer. AUC, BPH, CIs, cPSA, fPSA, PCP, ROC
73  2017 The role of sex steroid hormones in benign prostatic hyperplasia. AED, BPH, DHT, LUTS
74  2017 The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score≥7 prostate cancer from group of biopsy-based Gleason score≤6. NLR, RP
75  2017 Validation of the prostate health index in a predictive model of prostate cancer. fPSA, PHI
76  2017 [Use of prostate health index in diagnosing prostate cancer in Chinese men]. AUC, PHI, ROC
77  2016 Bipolar transurethral enucleation and resection of the prostate versus bipolar resection of the prostate for prostates larger than 60gr: A retrospective study at a single academic tertiary care center. B-TUERP, B-TURP, IPSS, QoL, RUV, TURS
78  2016 Clinical performance of prostate health index in men with tPSA>10ng/ml: Results from a multicentric European study. PCa, PHI
79  2016 Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer. CI, fPSA, mCRPC, OS, PFS, PHI
80  2016 Elevated prostate specific antigen and reduced 10-year survival among a cohort of Danish men consecutively referred from primary care to an urological department during 2005-2006. cPSA, PCa
81  2016 Influence of Long-Distance Bicycle Riding on Serum/Urinary Biomarkers of Prostate Cancer. fPSA, PCa
82  2016 Performance of the Prostate Health Index in predicting prostate biopsy outcomes among men with a negative digital rectal examination and transrectal ultrasonography. AUC, DRE, p2PSA, PCa, PHI, PSAD, TRUS
83  2016 Prostate Cancer Predictive Simulation Modelling, Assessing the Risk Technique (PCP-SMART): Introduction and Initial Clinical Efficacy Evaluation Data Presentation of a Simple Novel Mathematical Simulation Modelling Method, Devised to Predict the Outcome of Prostate Biopsy on an Individual Basis. fPSA, PCa, PCP-SMART, PCRD
84  2016 [Efficacy of periprostatic nerve block anesthesia for pain control in transrectal ultrasound- guided systematic prostate biopsy]. fPSA, PPNB, VAS
85  2016 [Trends in Gleason scores of Chinese prostate carcinoma from 1995 to 2014]. GS, NB, PCa, RP, TURP
86  2015 A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. fPSA, MSMB, ProtecT
87  2015 High PCA3 scores in urine correlate with poor-prognosis factors in prostate cancer patients. DRE, PCa, PCA3, PHI
88  2015 Perioperative prostate specific antigen levels among coronary artery bypass grafting patients: Does extracorporeal circulation and body temperature induce prostate specific antigen levels alterations? CABG, ECC
89  2015 Serum total prostate-specific antigen values in men with symptomatic prostate enlargement in Nigeria: role in clinical decision-making. ---
90  2015 Status of External Quality Assessment on Tumor Markers in China. AFP, CA125, CA15-3, CA19-9, CEA, CV, EQA
91  2015 The place of prostate rebiopsy in the diagnosis of prostate cancer. ASAP, DRE, HGPIN, IHC, PB, PCa, TRUS
92  2015 [A case of metastatic castration-resistant prostate cancer by abiraterone treatment]. fPSA, mCRPC, PSA, SPECT
93  2015 [Case-control studies of the relevant factors among Ningxia Hui and Han prostate cancer groups]. ARP, FBG, fPSA, TC, TG
94  2014 A prospective controlled study to determine the duration of antibiotherapy in the patients with elevated serum PSA levels. ---
95  2014 Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods. ---
96  2014 Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European study. AUC, AUC, fPSA, p2PSA, p2PSA, PCa, PHI
97  2014 Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the prostate health index (PHI) in a Chinese hospital-based biopsy population. AUC, DCA, fPSA, p2PSA, p2PSA, PCa, PHI
98  2014 Utility of digital rectal examination, serum prostate specific antigen, and transrectal ultrasound in the detection of prostate cancer: a developing country perspective. DRE, LUTS, PCa, TRUS
99  2014 [Influence of histological prostatitis on the clinical features of benign prostatic hyperplasia and prostate cancer]. AUR, BPH, HP, MFR, PCa, PSAD
100  2014 [Reproductive hormone levels and relevant parameters in middle-aged and older men in the urban area of Nanjing]. fT, SHBG, TT